Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today ...

On October 30, Matthew Fienup (Executive Director, Center for Economic Research and Forecasting) and Gerhard Apfelthaler, ...

Company reports $14.3 million in revenue in Q3'25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license and collaboration revenue - - Reports positive feedback from the FDA ...

Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license ...

Professionals across India are reassessing the MBA’s relevance as shifting skill demands, rising costs and a volatile job market make the degree a calculated risk rather than an automatic career boost ...

A powerful recruiting ecosystem to help you find career opportunities and engage with recruiters and companies.

Before the GLP-1 boom of recent years, the pharmaceutical industry had begun to shift away from blockbuster drugs towards specialized, personalized therapies, such as Cell & Gene Therapies (CGT’s) and ...

2030–2035: The market increases from USD 257.8 million to USD 327.2 million, delivering more than half (56%) of total decade ...

What Counts As A Graduate Student vs. Professional Student For Federal Student Aid? This question is about student loan ...

After announcing earlier this week the appointment of Andreas Wallnöfer, PhD, MBA, to its Board of Directors, Optigo ...

Dr. Andreas Wallnöfer joins Optigo Biotherapeutics' Board, bringing expertise from Jeito Capital, BioMedPartners, and Roche.